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Background: It is unknown if the greater reductions in bone mineral density (BMD) associated with initiation of
tenofovir disoproxil fumarate compared with abacavir in previously untreated HIV-infected participants in the
ACTG A5224s clinical trial were associatedwith potentially worsening tenofovir-related phosphaturia.
Methods: We correlated changes in BMD at the hip and spine with changes in phosphaturia [transtubular re-
absorption of phosphorus (TRP) and tubular maximum phosphate reabsorption per glomerular filtration rate
(TmP/GFR)] from entry throughweek 96 in those initiating tenofovir (n"134) versus abacavir (n"135) with efa-
virenz or atazanavir/ritonavir in A5224s. We also correlated changes in BMD with tenofovir AUC measured be-
tweenweeks 4 and 24.
Results: Changes in TRP and TmP/GFR through week 96 between the tenofovir and abacavir arms were not sig-
nificantly different (both P0.70) and did not differ with use of efavirenz versus atazanavir/ritonavir. There were
no significant correlations between changes in either TRP or TmP/GFR and with either hip or spine BMD
in the tenofovir arms. Tenofovir AUC was significantly correlated with changes in hip BMD, but not spine BMD,
at week 24 (r"#0.22, P"0.028) andweek 48 (r"#0.26, P"0.010), but not at week 96 (r"#0.14, P"0.18).
Conclusions: Changes in phosphaturia were not different between the tenofovir and abacavir arms in A5224s.
Changes in hip and spine BMDwith tenofovir were not related to changes in phosphaturia. However, tenofovir ex-
posure wasweakly associatedwith changes in hip BMD throughweek 48.
Introduction
Compared with the HIV-uninfected population, fracture rates are
higher in thosewhoareHIV infected.1,2 In addition, osteopenia, as-
sessed as reduced bone mineral density (BMD), is more frequent
and of greater severity in HIV-infected patients, particularly in
those receiving ART incorporating tenofovir disoproxil fumarate.3–6
The mechanism for tenofovir-induced reductions in BMD is widely
believed to be due to urine phosphate wasting as a consequence
of renal proximal tubulopathy that frequently accompanies teno-
fovir use. A recent study suggested that patients receiving tenofo-
vir chronically had continued BMD loss due to, in part, urinary
phosphate losses.7 However, it is not known if phosphaturia ex-
plains the BMD reductions seenwith initial tenofovir use.8
An alternative hypothesis for why tenofovir may lead to osteo-
penia is that circulating tenofovir concentrations (and by correl-
ation bone levels of tenofovir) may directly increase bone
turnover.9,10 Indeed, with regimens containing tenofovir alafena-
mide fumarate, lower plasma levels of tenofovir and lower BMD
losses were seen when compared with therapies containing teno-
fovir disoproxil fumarate.11,12 This suggests that plasma levels of
tenofovir are associated with bone loss directly, although this has
not yet beenproven.
Therefore, we sought to test these competing hypotheses in a
secondary analysis of ACTG A5224s, which found that BMD losses
were more pronounced with initiation of regimens containing
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tenofovir disoproxil fumarate compared with those containing
abacavir.8
Methods
Study design and procedures
AIDS Clinical Trials Group A5224s was a metabolic substudy of A5202
(ClinicalTrials.gov NCT00118898) in which ART-naive study participants
from AIDS Clinical Trials Group sites in the United States and Puerto
Rico aged16 years and with an HIV-1 RNA level.1000 copies/mL were
randomized to a blinded NRTI fixed-dose component, abacavir/lamivu-
dine (600mg/300mg) or tenofovir disoproxil fumarate/emtricitabine
(300mg/200mg), with either the open-label PI atazanavir/ritonavir
(300mg/100mg) or the NNRTI efavirenz (600mg).
We performed a post hoc analysis of available data from both A5224s
and A5202. The bone DXA and estimated glomerular filtration rate (eGFR)
data collected at entry, weeks 24, 48 and 96 have been previously
published.8,13
Fasting serum and urine phosphate levels were also obtained at these
study visits. Urine creatinine was measured centrally at Quest Diagnostics
using a Jaffe colorimetric assay on a Beckman Coulter/Olympus platform.
Urine phosphate was also measured centrally at Quest Diagnostics using a
spectrophotometric assay using a molybdate reaction. Serum creatinine
and serum phosphate weremeasured locally. We estimated urinary phos-
phate wasting as both transtubular reabsorption of phosphorus (TRP) and
tubular maximum phosphate reabsorption per GFR (TmP/GFR). TRP was
calculated as 1– [serum creatinine%urine phosphate]/[urine creatin-
ine% serum phosphate] and is reported here as a percentage. TmP/GFR
was calculated as TRP% serum phosphate (if TRP 0.86) or as 0.3% {TRP/
[1 – (0.8% TRP)]}% serumphosphate (if TRP.0.86).14,15 GFRwas estimated
using the 2009CKD-EPI creatinine equation.16
Sparse tenofovir plasma concentrations were collected between weeks
4 and 24. Individual Bayesian estimates of plasma oral clearance values of
tenofovir were estimated from a two-compartment population pharmaco-
kinetic model using the tenofovir concentrations.17 AUC values were calcu-
lated based on individual clearance values where AUC"dose/clearance;
the actual dose of tenofovir in 300mg of tenofovir disoproxil fumarate was
136mg. Tenofovir concentrationswere notmeasured beyondweek24.
Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences and
GlaxoSmithKline/ViiV provided the studymedications, but had no access to
the primary data. The decision to publish themanuscript was solely that of
the academic authors. All the authors participated in the trial design, data
analysis and/or preparation of themanuscript and all the authors vouch for
the completeness and accuracy of the reported data.
Study participants
To be included in themain A5202 trial participants were required to have a
screening CLCR by Cockcroft–Gault .60mL/min. To be included in the sub-
study A5224s, participants also could not have uncontrolled thyroid dis-
ease, hypogonadism, Cushing’s syndrome or American Diabetes
Association-defined diabetes mellitus. The participants also were excluded
if using or had planned use during the study period of the growth hormone,
anabolic steroids, glucocorticoids or osteoporosismedications.
Ethics
The human subjects ethics committee at each participating centre
approved the study protocol andwritten informed consentwas provided by
all participants in compliance with the human experimentation guidelines
of theUSDepartment of Health andHumanServices.
Statistical analysis
This analysis had three main objectives. First, we assessed the effects of
NRTI backbone on phosphaturia changes. Second, we sought to determine
the associations between changes in phosphaturia and changes in lumbar
spine and hip BMD at 24, 48 and 96 weeks in the overall study population
and by treatment arm in A5224s. We also determined if use of atazanavir/
ritonavir versus efavirenz or if changes in eGFR modified the relationships
between phosphaturia and tenofovir exposure with BMD. Third, we wished
to correlate circulating tenofovir exposure (AUC) with lumbar spine and hip
BMD at 24, 48 and 96 weeks and with phosphaturia at week 24 in the two
tenofovir-containing regimens in A5224s. The first objective was assessed
using both simple and multivariable linear regressions whereas Spearman
correlationswere used to address the second and third objectives.
The sample size estimatewas basedon the primary A5224s objective of
week 96 lipoatrophy prevalence.18 Complete details of the randomization
procedures are described elsewhere.19
P,0.05 was considered statistically significant and nominal values are
reportedwithout adjustment formultiple comparisons. Analyses were per-
formed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 269 participants in A5224s were included in this analysis.
Overall, 85% were men and 47% were non-Hispanic white. The
median age, CD4 cell count and HIV-1 RNA levels were, respect-
ively, 38years, 233 cells/lL and4.62 log10 copies/mL.
8
BMD changes
The changes in lumbar spine and hip BMD from entry to
week 96 with use of tenofovir versus abacavir have previously
been published.8 The prevalence of osteopenia (defined as having
a t score #1 at either the spine or the hip) overall at entry
was 39%. In brief, the mean lumbar spine BMD was reduced from
entry to week 96 by 3.35% versus 1.35% in the tenofovir- and
abacavir-containing study arms, respectively, whereas the mean
hip BMD was reduced by 3.96% versus 2.61% through week 96 in
these same treatment arms.
Phosphaturia changes
As shown in Table 1, the TRP and TmP/GFR values at entry were
well-balanced amongst the four study groups. The changes in TRP
and TmP/GFR in each of the four study arms are also shown in
Table 1. Reductions in both phosphaturia measures indicate less
phosphate reabsorption (or more urinary phosphate wasting).
Mean (SD) absolute changes in TRP and TmP/GFR in the entire study
group were modest at #1.78% (6.59%) and #0.28 (0.92) mg/dL,
respectively, from entry to week 96 and were similar amongst the
four arms.
We then examined the changes in TRP and TmP/GFR by NRTI
and NNRTI/PI treatment components (Figure 1). Changes in TRP
were similar in the tenofovir/emtricitabine and abacavir/lamivu-
dine groups from entry through week 96. Changes in TmP/GFR be-
tween the tenofovir/emtricitabine and abacavir/lamivudine
groups as well as between the atazanavir/ritonavir and efavirenz
groups fromentry toweek 96were also similar.
We then estimated the NRTI effects on phosphaturia changes
and assessed treatment effects by the NNRTI/PI components
as well as by change in eGFR from entry to week 96. The mean
(95% CI) change in TRP (%) was #1.90 (#3.25 to #0.55) for
BMD and phosphaturia with tenofovir disoproxil fumarate JAC
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Table 1. Mean (SD; n) changes in phosphaturia for all four A5224s study treatment arms
EFV! TDF/FTC,
N"69
EFV!ABC/3TC,
N"70
ATV/RTV! TDF/FTC,
N"65
ATV/RTV!ABC/3TC,
N"65
Total,
N"269
TRP (%)
entry 89.17 (6.10; 66) 90.34 (4.58; 66) 88.90 (5.27; 57) 89.54 (5.38; 61) 89.51 (5.36; 250)
change from entry to week 24 0.26 (5.93; 57) #1.50 (6.22; 60) #0.71 (6.80; 50) 0.40 (6.32; 54) #0.40 (6.31; 221)
change from entry to week 48 #0.65 (5.99; 54) #2.20 (6.77; 55) #0.66 (5.82; 45) 0.51 (5.99; 55) #0.75 (6.21; 209)
change from entry to week 96 #1.44 (7.67; 49) #1.86 (6.20; 50) #2.41 (6.47; 44) #1.43 (5.98; 45) #1.78 (6.59; 188)
TmP/GFR (mg/dL)
entry 3.43 (0.85; 66) 3.56 (0.83; 66) 3.40 (0.72; 57) 3.39 (0.68; 61) 3.45 (0.77; 250)
change from entry to week 24 #0.19 (0.83; 57) #0.14 (0.90; 60) #0.13 (0.58; 50) 0.27 (0.89; 54) 0.00 (0.83; 221)
change from entry to week 48 #0.21 (0.82; 54) #0.30 (0.89; 55) #0.08 (0.64; 45) 0.05 (0.75; 55) #0.14 (0.79; 209)
change from entry to week 96 #0.32 (1.06; 49) #0.30 (0.84; 50) #0.29 (0.73; 44) #0.20 (1.04; 45) #0.28 (0.92; 188)
EFV, efavirenz; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; ATV, atazanavir; RTV, ritonavir.
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Figure 1. Changes in phosphaturia from entry to week 96 by NRTI and NNRTI/PI treatment components. (a) and (b), respectively, show absolute
mean (95% CI) changes in TRP (%) in the NRTI treatment components (TDF/FTC and ABC/3TC) and in the NNRTI/PI treatment components (EFV and
ATV/RTV). (c) and (d), respectively, show absolute mean (95% CI) changes in TmP/GFR (mg/dL) in the NRTI and NNRTI/PI treatment components.
TDF/FTC, tenofovir/emtricitabine; ABC/3TC, abacavir/lamivudine; EFV, efavirenz; ATV/RTV, atazanavir/ritonavir.
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tenofovir/emtricitabine and #1.66 (#2.99 to #0.32) for abacavir/
lamivudine, which produces a mean difference (95% CI) of
0.24 (#1.66 to 2.14) (P"0.80). The mean (95% CI) absolute
changes in TmP/GFR (mg/dL) were #0.31 (#0.49 to #0.12) for
tenofovir/emtricitabine and #0.25 (#0.44 to #0.07) for abacavir/
lamivudine, with a mean (95% CI) difference of 0.05 (#0.21 to
0.32) (P"0.70). In exploratory analyses, we did not find significant
interactions between the NRTI component and either the
NNRTI/PI component or the change in eGFR through week 96
(all P.0.13).
Correlations between changes in phosphaturia and BMD
We then correlated changes in both TRP and TmP/GFR with
changes in BMD at the hip and spine in the overall study group and
by NRTI treatment components (Table 2). In the overall study
group, we found weak inverse correlations between changes in
TRP and changes in hip BMD from entry to week 24 (#0.17,
P" 0.013) and week 48 (#0.17, P"0.02), thereby suggesting that
increased urinary phosphate losses were correlated with less BMD
loss at the hip at these time points. These correlations were driven
primarily by significant inverse correlations in the abacavir/
lamivudine-containing regimens. However, there was not a signifi-
cant correlation between TRP andhip BMDatweek 96 in the overall
study group. We did not find any significant correlations between
changes in phosphaturia, assessed as either TRP or TmP/GFR, and
BMD at the hip or spine in the tenofovir/emtricitabine arms.We did
find, however, a significant, albeit weak, positive correlation
(0.23, P"0.033) between increased urinary phosphate reabsorp-
tion and increased spine BMD in the abacavir-containing arms
fromentry toweek 96.
In additional exploratory analyses, we then assessed the po-
tential modifications of the effects of changes in phosphaturia on
changes in hip and spine BMD by NNRTI/PI component and change
in eGFR from entry to week 96. These analyses were performed to
determine if these additional variables would affect renal clear-
ance of phosphate and consequently unmask associations be-
tween phosphaturia and BMD change. No significant interactions
were found in our models (data not shown). In additional models,
we also did not find any significant interactions between the NRTI
component and change in eGFR on the change in either hip or
spine BMD.
Correlations between tenofovir exposure and changes in
BMD and phosphaturia
The mean (SD) tenofovir AUC (mgh/L) exposures estimated
through sparse PK analysis of concentrations measured between
weeks 4 and 24 in the overall group, in the efavirenz groups and in
the atazanavir/ritonavir groups were 3.34 (1.19), 3.07 (1.30) and
3.61 (0.99), respectively. We found significant, but weak, correl-
ations between tenofovir AUC and changes in hip BMD from
entry to week 24 (q"#0.22, P"0.028) and from entry to week
48 (q"#0.26, P"0.010), but not through week 96 (q"#0.14,
P"0.18). There were no significant correlations between tenofovir
AUC and spine BMD at any time point or between tenofovir AUC
and either TRP or TmP/GFR from entry to week 24 (data not
shown).
Discussion
The aetiology of BMD loss with initiation of ART is likelymultifactor-
ial, with growing evidence supporting immune reconstitution with
increased net bone resorption as one possible explanation.20
However, the reasons why regimens containing tenofovir diso-
proxil fumarate result in even greater BMD loss compared with
other regimens remain unclear. The present study is, to our know-
ledge, the first systematic and comparative evaluation of changes
in phosphaturia and correlation with changes in BMD in HIV-
infected patients initiating ART with either tenofovir/emtricitabine
or abacavir/lamivudine. We did not find evidence supporting a re-
lationship between worsening urinary phosphate wasting and re-
ductions in either the lumbar spine or the hip with use of tenofovir.
However, instead we found significant, albeit weak, relationships
between greater tenofovir exposures during the first 24 weeks of
therapy and reduced hip BMD through week 48 of the trial, though
not throughweek 96 of therapy. It should be noted that the reduc-
tions in BMD in A5224s occurred primarily during the first 48weeks
of therapy and plateaued or improved modestly afterwards to
week 96, which may explain the lack of association with tenofovir
exposure and changes in BMDat this latter timepoint.
These results corroborate those found by Hamzah et al.21 in a
cross-sectional study of 293 men receiving tenofovir disoproxil fu-
marate chronically. In that study, the investigators found no rela-
tionship between phosphaturia and BMD.21 Moreover, in a trial
Table 2. Correlations (r; P) between changes in TRP or TmP/GFR and changes in BMD from entry through week 96
Urine phosphate reabsorption Study week
Overall TDF ABC
hip spine hip spine hip spine
TRP 24 #0.17; 0.013 #0.09; 0.19 #0.10; 0.33 #0.03; 0.77 #0.23; 0.018 #0.11; 0.27
48 #0.17; 0.020 #0.09; 0.22 #0.09; 0.40 0.05; 0.63 #0.26; 0.012 #0.20; 0.058
96 #0.06; 0.47 0.05; 0.55 0.06; 0.60 0.04; 0.73 #0.18; 0.090 0.06; 0.60
TmP/GFR 24 #0.05; 0.46 #0.01; 0.92 0.00; 0.99 #0.09; 0.39 #0.12; 0.24 0.05; 0.62
48 #0.08; 0.26 #0.07; 0.32 #0.17; 0.11 #0.10; 0.33 #0.04; 0.71 #0.05; 0.63
96 #0.03; 0.70 0.13; 0.082 0.04; 0.73 0.03; 0.77 #0.12; 0.27 0.23; 0.033
TDF, tenofovir disoproxil fumarate; ABC, abacavir.
Items in bold are correlations that were statistically significant.
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comparing continued emtricitabine/tenofovir disoproxil fumarate/
efavirenz use with the switch to darunavir/ritonavir monotherapy,
a significant improvement in BMD of the hip and spine in the
nucleos(t)ide-sparing, PI monotherapy switch arm was observed
comparedwith the tenofovir-containing arm after 48weeks; how-
ever, no changes in phosphaturiawere noted between study arms,
thereby suggesting a lack of a relationship between phosphaturia
and BMD change with tenofovir use.22 However, our results
stand in contrast to a recent study by Casado et al.7who examined
90 patients who had been receiving tenofovir for a median of
38months. Greater phosphaturiawas significantly related to lower
BMD and predicted additional BMD loss over time;7 however, this
study did notmeasure tenofovir concentrations to examine the re-
lationship between circulating exposure of tenofovir and bone loss.
If we assume that the greater reductions in BMDwith tenofovir are
indeed due to circulating exposure with consequent direct bone
toxicity and not due to urinary phosphate wasting, how can one
explain the apparently disparate results between these two stud-
ies? It is plausible that greater tenofovir circulating concentrations,
and by extension greater tenofovir renal proximal tubule concen-
trations, increase the risk and severity of proximal tubulopathy and
worsening urinary phosphate wasting. If so, greater circulating
concentrations of tenofovir may lead both to phosphaturia and to
bone toxicity, but this does not necessarily mean that phosphatu-
ria is causally related to bone loss; in otherwords, these two poten-
tially pathological results of increased circulating tenofovir
concentrationsmay be ‘true, true andunrelated’.
Inmultivariablemodels incorporating the NNRTI/PI component
and eGFR, we did not find differences in changes in phosphate
wasting between tenofovir/emtricitabine and abacavir/lamivu-
dine. This result corroborates the findings from smaller trials com-
paring tenofovir disoproxil fumarate with abacavir in previously
ART-naive patients.23,24 The relatively small changes in urinary
phosphate wasting, measured as either TRP or as TmP/GFR, in our
current study, both overall and specifically in the tenofovir-
containing regimens, may be a result of offsetting factors. HIV in-
fection itself leads to renal proximal tubulopathy,25 and reductions
in viraemia with ART initiation, even with tenofovir, may alleviate
this phenomenon.26 Thus, any potential increase in tenofovir diso-
proxil fumarate-induced urinary phosphate wasting may be
blunted during initial therapy, but thenmay becomemore obvious
with chronic therapy after viraemia is controlled, as was previously
found in a trial of virologically suppressed patients switching to ei-
ther tenofovir or abacavir.27
We acknowledge that the development of tenofovir alafena-
mide with resulting lower circulating tenofovir concentrations and
tenofovir disoproxil fumarate-sparing ART regimensmayminimize
the concern for tenofovir-induced osteopenia and subsequent
fracture risk in resource-replete settings.11,28 However, the use of
tenofovir disoproxil fumarate is becoming more widespread in
resource-limited settings and thus presents continued concerns
for bone safety in these populations. In addition, increasing teno-
fovir disoproxil fumarate use has been advocated in high-risk unin-
fected persons, both in resource-replete and constrained settings,
as a means to prevent HIV infection. In fact, tenofovir use has
been linked with modest reductions in BMD even in these HIV-
negative pre-exposure prophylaxis populations.29 Thus, under-
standing themechanisms underlying tenofovir-related osteopenia
remains clinically significant and relevant.
The effects of NNRTIs or PIs on phosphaturia have not been
fully examined. Our results (Figure 1b and d) suggest that
atazanavir/ritonavir-containing regimens did not appreciably
impact either TRP or TmP/GFR during the first 48 weeks of treat-
ment, but these parameters then fell from week 48 to week 96.
Conversely, both phosphaturia measures fell steadily with the
efavirenz regimens from entry to week 48, but then plateaued
afterwards to week 96. The changes in TRP and TmP/GFR levels
from entry to week 96 were then similar in each of the four study
groups. It is possible that efavirenz initiation led to the induction
of 24-hydroxylase activity and consequently reduction of vita-
min D.30 If so, then this could have led to an increase in parathy-
roid hormone31 and increased phosphaturia during the first
48 weeks of treatment, although we cannot prove this as we did
not measure vitamin D and parathyroid hormone levels in this
study. The lack of changes in phosphaturia during the first
48 weeks of therapy with atazanavir/ritonavir, but then the
increased phosphaturia during the next 48 weeks is not easily
explained and, so, these results will require corroboration in fu-
ture studies.
There are several limitations to these analyses that should be
acknowledged. First, we did not measure tenofovir concentrations
throughout the entire study period. Second, we did not measure
bone turnovermarkers, vitamin D levels, parathyroid hormone lev-
els or other bone or renal measures that might have suggested
additional pathways by which tenofovir may have exacerbated
bone loss in this population. This is particularly important given
that the significant relationships we identified between tenofovir
exposure and BMD reductions were weak and limited to the hip,
thereby suggesting additional mechanisms of bone loss are likely.
Third, we also did not correct for multiple testing, which may have
led to false positive findings.
In conclusion, we did not find that the increased BMD loss with
tenofovir disoproxil fumarate initiation in ACTG A5224swas associ-
ated with changes in urinary phosphate wasting. Instead, we
foundweak relationships between greater circulating tenofovir ex-
posures and hip BMD reductions through the first 48 weeks of
treatment. Additional studies arewarranted to determine the aeti-
ologies of bone losswith tenofovir.
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